In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Tenaya Therapeutics in a report issued on ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers ...

The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund ...

Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free ...

RWA Wealth Partners took a mild haircut on its CVS Health stake, slicing 7.5% off its holdings in Q4. Despite this trim, ...